CHEMBIO DIAGNOSTICS INC's ticker is CEMI and the CUSIP is 163572209. A total of 80 filers reported holding CHEMBIO DIAGNOSTICS INC in Q4 2020. The put-call ratio across all filers is 2.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,000 | -37.5% | 21,012 | 0.0% | 0.00% | – |
| Q3 2022 | $8,000 | -42.9% | 21,012 | 0.0% | 0.00% | – |
| Q2 2022 | $14,000 | -17.6% | 21,012 | 0.0% | 0.00% | – |
| Q1 2022 | $17,000 | -29.2% | 21,012 | 0.0% | 0.00% | – |
| Q4 2021 | $24,000 | -55.6% | 21,012 | -0.9% | 0.00% | – |
| Q3 2021 | $54,000 | +1.9% | 21,212 | +17.8% | 0.00% | – |
| Q2 2021 | $53,000 | -15.9% | 18,000 | 0.0% | 0.00% | – |
| Q1 2021 | $63,000 | -75.3% | 18,000 | -66.4% | 0.00% | -100.0% |
| Q4 2020 | $255,000 | +16.4% | 53,541 | +18.2% | 0.00% | 0.0% |
| Q3 2020 | $219,000 | +48.0% | 45,278 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $148,000 | -14.5% | 45,278 | +33.9% | 0.00% | 0.0% |
| Q1 2020 | $173,000 | +11.6% | 33,815 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $155,000 | +70.3% | 33,815 | +128.2% | 0.00% | – |
| Q3 2019 | $91,000 | +1.1% | 14,815 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $90,000 | -37.9% | 14,815 | +6.7% | 0.00% | 0.0% |
| Q3 2018 | $145,000 | – | 13,882 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Penbrook Management LLC | 344,060 | $1,634,000 | 1.26% |
| Union Square Park Capital Management, LLC | 400,000 | $1,900,000 | 0.76% |
| P.A.W. CAPITAL CORP | 100,000 | $475,000 | 0.42% |
| PRECEPT MANAGEMENT LLC | 150,000 | $713,000 | 0.29% |
| Newbridge Financial Services Group, Inc. | 73,500 | $349,000 | 0.29% |
| SANDERS MORRIS HARRIS LLC | 183,584 | $990,000 | 0.22% |
| FRIESS ASSOCIATES LLC | 555,000 | $2,636,000 | 0.19% |
| PERRITT CAPITAL MANAGEMENT INC | 30,651 | $146,000 | 0.09% |
| Ikarian Capital, LLC | 219,109 | $1,041,000 | 0.05% |
| SEGALL BRYANT & HAMILL, LLC | 705,823 | $3,352,000 | 0.04% |